Chimerix | Investor Conference Presentation Deck | 32 slides

Chimerix · 2021-11
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

3
coverage by narrative range · generated from this deck JSON

Slide inventory

32
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
front_matter
04
Includes a diagram of brain regions and a dot plot showing patient age distribution across different midline sites.diagnose_problem
Open slide detailBeat · Problem
05
The slide uses a biological pathway diagram to explain the drug's mechanism of action.present_solution
Open slide detailBeat · Problem
06
present_framework
07
The slide details specific RANO criteria for glioma assessment and censoring rules for efficacy analysis.present_framework
08
RANO-HGG criteria table defines response based on T1-Gd+, T2/FLAIR, new lesions, corticosteroids, and clinical status.analyze_data
09
RANO-LGG stands for Response Assessment in Neuro-Oncology for Low-Grade Glioma.present_framework
10
Standard clinical trial baseline characteristics table.analyze_data
11
summarize
12
The table lists specific preferred terms occurring in more than one patient.analyze_data
13
Includes footnotes detailing criteria assessment and patient exclusions.analyze_data
14
The chart displays individual patient responses to treatment, with bars colored by clinical outcome (PD, SD, NE, PR, CR).analyze_data
15
The plot includes clinical trial metrics for duration and time to response.analyze_data
16
The slide includes specific clinical definitions for response categories and footnotes explaining patient exclusions and criteria.analyze_data
17
Clinical trial data visualization showing patient-level response to treatment.analyze_data
18
The slide uses a before-after-bridge framework to demonstrate treatment efficacy.illustrate_case
19
Includes a risk table at the bottom and 95% confidence intervals shaded in gray.analyze_data
20
Includes a risk table at the bottom showing patient counts (n) at 3-month intervals.analyze_data
21
The chart tracks individual patient 'Total Dex Dose (mg)' over months from first dose.analyze_data
22
BICR = Blinded Independent Central Review; RANO-HGG/LGG = Response Assessment in Neuro-Oncology criteria for High/Low Grade Glioma.summarize
Open slide detailBeat · Solution
23
other
Open slide detailBeat · Solution
24
appendix
Open slide detailBeat · Solution
25
The chart uses bubble plots to represent survival probability distributions across different studies.diagnose_problem
Open slide detailBeat · AgitateLoop · Cost Of Inaction
26
RANO-HGG refers to Response Assessment in Neuro-Oncology for High-Grade Gliomas. BICR refers to Blinded Independent Central Review.analyze_data
Open slide detailBeat · Solution
27
The plot shows individual patient responses; asterisks indicate change > 100%.analyze_data
Open slide detailBeat · Solution
28
The slide uses a dual-axis line chart to correlate tumor size reduction with performance status improvement, supported by longitudinal MRI scans.illustrate_case
Open slide detailBeat · SolutionLoop · Before After
29
The slide uses a longitudinal chart to track three metrics over 18 months alongside MRI scans.illustrate_case
Open slide detailBeat · SolutionLoop · Before After
30
The slide compares two different RANO criteria (HGG vs LGG) for the same patient cohort to demonstrate clinical response.analyze_data
Open slide detailBeat · Solution
31
The table highlights that RANO responders show significantly higher PFS and OS rates compared to non-responders.analyze_data
Open slide detailBeat · Solution
32
The slide presents clinical trial data (ORR, DOR, PFS, OS) using RANO-HGG and RANO-LGG criteria.summarize
Open slide detailBeat · Solution